Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis DOI Creative Commons
Heng Chen, Gefei He, Juanjuan Huang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 17, 2024

Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated real-world clinical settings.

Language: Английский

Dermatologic toxicities related to cancer immunotherapy DOI Creative Commons
Yosra Vaez-Gharamaleki, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh

et al.

Toxicology Reports, Journal Year: 2025, Volume and Issue: unknown, P. 102021 - 102021

Published: April 1, 2025

Language: Английский

Citations

0
Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation DOI Creative Commons

Ahmed Ezzat,

Mohga Shafiek,

S. Shawki

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 13, 2025

Language: Английский

Citations

0
Quoi de neuf en dermatologie clinique ? DOI
A. Du‐Thanh

Annales de Dermatologie et de Vénéréologie - FMC, Journal Year: 2024, Volume and Issue: 4(8), P. 8S1 - 8S12

Published: Nov. 27, 2024

Citations

0
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis DOI Creative Commons
Heng Chen, Gefei He, Juanjuan Huang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 17, 2024

Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated real-world clinical settings.

Language: Английский

Citations

0